Concord Biotech Limited (BOM:543960)
1,569.30
-6.70 (-0.43%)
At close: Aug 21, 2026
Concord Biotech Revenue
Concord Biotech had revenue of 2.57B INR in the quarter ending June 30, 2026, with 26.23% growth. This brings the company's revenue in the last twelve months to 11.08B, down -6.72% year-over-year. In the fiscal year ending March 31, 2026, Concord Biotech had annual revenue of 10.55B, down -12.10%.
Revenue (ttm)
11.08B
Revenue Growth
-6.72%
P/S Ratio
14.83
Revenue / Employee
6.83M
Employees
1,624
Market Cap
164.38B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 10.55B | -1.45B | -12.10% |
| Mar 31, 2025 | 12.00B | 1.83B | 18.01% |
| Mar 31, 2024 | 10.17B | 1.64B | 19.20% |
| Mar 31, 2023 | 8.53B | 1.40B | 19.67% |
| Mar 31, 2022 | 7.13B | 959.91M | 15.56% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Jubilant Pharmova | 86.08B |
| Granules India | 56.32B |
| J. B. Chemicals & Pharmaceuticals | 41.48B |
| Viyash Scientific | 35.75B |
| AstraZeneca Pharma India | 24.32B |
| Caplin Point Laboratories | 22.87B |
| Rubicon Research | 19.36B |
| Sanofi India | 18.05B |
Concord Biotech News
- 19 days ago - Concord Biotech Transcript: Q1 26/27 - Transcripts
- 19 days ago - Concord Biotech Quarterly report: Q1 2027 - Filings
- 19 days ago - Concord Biotech Slides: Q1 2027 - Filings
- 2 months ago - Concord Biotech Transcript: Q4 25/26 - Transcripts
- 2 months ago - Concord Biotech Quarterly report: Q4 2026 - Filings
- 2 months ago - Concord Biotech Slides: Q4 2026 - Filings
- 2 months ago - Concord Biotech Annual report: Q4 2026 - Filings
- 6 months ago - Concord Biotech Transcript: Q3 25/26 - Transcripts